新批准推动血癌药物发展。
New Approvals Advancing Blood Cancer Medicine.
出版信息
Blood Cancer Discov. 2025 Jan 8;6(1):5-9. doi: 10.1158/2643-3230.BCD-24-0300.
Abstract
Recent advancements in clinical tools for blood cancers are highlighted in this article, adapted from the 14th edition of the annual AACR Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/) to the US Congress and the public.
摘要
本文重点介绍了血液癌症临床工具的最新进展，该文改编自年度美国癌症研究协会（AACR）癌症进展报告第14版（https://cancerprogressreport.aacr.org/progress/），面向美国国会和公众发布。
相似文献
1
New Approvals Advancing Blood Cancer Medicine.新批准推动血癌药物发展。
Blood Cancer Discov. 2025 Jan 8;6(1):5-9. doi: 10.1158/2643-3230.BCD-24-0300.
2
A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?美国生物类似药批准的系统评价：FDA 需要什么证据，制造商如何回应？
J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234.
3
How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease.美国食品药品监督管理局（FDA）监管流程和程序的改进如何促成了有史以来第一种常见肝脏疾病治疗药物的获批。
Acta Pharmacol Sin. 2025 Mar;46(3):515-524. doi: 10.1038/s41401-024-01396-4. Epub 2024 Nov 7.
4
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022.2020 - 2022财年新药和生物制品许可申请批准中的真实世界证据
Clin Pharmacol Ther. 2025 Jul;118(1):85-89. doi: 10.1002/cpt.3688. Epub 2025 Apr 25.
5
New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22.新癌症药物获批情况：2019 - 2022年美国食品药品监督管理局向临床医生报告的重要临床试验不确定性不到一半
Health Aff (Millwood). 2025 Jul;44(7):830-838. doi: 10.1377/hlthaff.2024.01134.
6
Recent and anticipated novel drug approvals (1Q 2025 through 4Q 2025).近期及预期的新型药物批准情况（2025年第一季度至2025年第四季度）。
Am J Health Syst Pharm. 2025 Jun 26;82(13):e600-e606. doi: 10.1093/ajhp/zxaf030.
7
Patient Experience Data (PED) in 2019-2023 US FDA NME Drug Approvals: Analysis and Recommendations.2019 - 2023年美国食品药品监督管理局新分子实体药物批准中的患者体验数据：分析与建议
Ther Innov Regul Sci. 2025 Jul;59(4):859-870. doi: 10.1007/s43441-025-00788-w. Epub 2025 May 9.
8
A Year of Advances in Precision Therapy for Blood Cancers.血液癌症精准治疗的一年进展。
Blood Cancer Discov. 2023 Nov 1;4(6):423-426. doi: 10.1158/2643-3230.BCD-23-0193.
9
Has FDA's Drug Development Tools Qualification Program Improved Drug Development?美国食品药品监督管理局（FDA）的药物开发工具资格认定计划是否改进了药物研发？
Ther Innov Regul Sci. 2025 May 4. doi: 10.1007/s43441-025-00790-2.
10
A Comprehensive Retrospective Analysis of Trends and Strategic Implications of 505(b)(2) Approvals (2019-2023).对505(b)(2)批准（2019 - 2023年）的趋势及战略影响的全面回顾性分析
Ther Innov Regul Sci. 2025 Jul;59(4):790-807. doi: 10.1007/s43441-025-00775-1. Epub 2025 May 5.
本文引用的文献
1
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Imetelstat用于复发或对促红细胞生成素刺激剂难治的低危骨髓增生异常综合征患者（IMerge）：一项多中心、随机、双盲、安慰剂对照的3期试验。
Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1.
2
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.米替福新通过改变脂肪酸代谢诱导铁死亡作为急性髓系白血病的治疗策略。
Nat Cancer. 2024 Jan;5(1):47-65. doi: 10.1038/s43018-023-00653-5. Epub 2023 Oct 30.
3
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.Quizartinib 联合化疗治疗新诊断的 FLT3 内部串联重复阳性急性髓系白血病患者（QuANTUM-First）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.
4
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
5
AACR Cancer Progress Report 2015.2015年美国癌症研究协会癌症进展报告
Clin Cancer Res. 2015 Oct 1;21(19 Suppl):S1-128. doi: 10.1158/1078-0432.CCR-15-1846.
6
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.FLT3内部串联重复和酪氨酸激酶结构域突变对急性髓系白血病的预后意义：一项荟萃分析。
Leukemia. 2005 Aug;19(8):1345-9. doi: 10.1038/sj.leu.2403838.
Zotero 插件